Colorectal cancer chemoprevention by mesalazine and its derivatives

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Stolfi, Carmine ^a   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 5 AMINO N HYDROXYBENZAMIDE; ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESALAZINE; UNCLASSIFIED DRUG; WNT PROTEIN; EGFR PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DOSE RESPONSE; DRUG SYNTHESIS; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; REVIEW; COLORECTAL TUMOR; DNA REPLICATION; DRUG EFFECT; GENETICS; INFLAMMATORY BOWEL DISEASE; PATHOLOGY; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY;

CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA REPLICATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PPAR GAMMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84863665380     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/980458     Document Type: Review

References (54)

1. Abraham C., Cho J. H., Inflammatory bowel disease New England Journal of Medicine 2009 361 21 2066 2078
2. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., Williams C., Price A., Talbot I., Forbes A., Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis Gastroenterology 2004 126 2 451 459 (Pubitemid 38182302)
3. Gupta R. B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., Bodian C., Ullman T., Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study Gastroenterology 2007 133 4 1099 1105 (Pubitemid 47494461)
4. Eaden J. A., Abrams K. R., Mayberry J. F., The risk of colorectal cancer in ulcerative colitis: a meta-analysis Gut 2001 48 4 526 535 (Pubitemid 32234798)
5. Askling J. A., Dickman P. W., Karlen P., Family history as a risk factor for colorectal cancer in inflammatory bowel disease Gastroenterology 2001 120 6 1356 1362 (Pubitemid 32322309)
6. Heuschen U. A., Hinz U., Allemeyer E. H., Stern J., Lucas M., Autschbach F., Herfarth C., Heuschen G., Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis Gastroenterology 2001 120 4 841 847 (Pubitemid 32193181)
7. Ekbom A., Helmick C., Zack M., Adami H. O., Ulcerative colitis and colorectal cancer: a population-based study New England Journal of Medicine 1990 323 18 1228 1233 (Pubitemid 20366527)
8. Torres J., de Chambrun G. P., Itzkowitz S., Sachar D. B., Colombel J. F., Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease Alimentary Pharmacology and Therapeutics 2011 34 5 497 508
9. Choi P. M., Zelig M. P., Similarity of colorectal cancer of Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention Gut 1994 35 7 950 954
10. Lennard-Jones J. E., Morson B. C., Ritchie J. K., Williams C. B., Cancer surveillance in ulcerative colitis. Experience over 15 years The Lancet 1983 2 8342 149 152 (Pubitemid 13067438)
11. Rhodes J. M., Campbell B. J., Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared Trends in Molecular Medicine 2002 8 1 10 16 (Pubitemid 34044673)
12. Ahmadi A., Polyak S., Draganov P. V., Colorectal cancer surveillance in inflammatory bowel disease: the search continues World Journal of Gastroenterology 2009 15 1 61 66
13. Koehne C. H., Dubois R. N., COX-2 inhibition and colorectal cancer Seminars in Oncology 2004 31 7 12 21 (Pubitemid 38879410)
14. Rao C. V., Reddy B. S., NSAIDs and chemoprevention Current Cancer Drug Targets 2004 4 1 29 42 (Pubitemid 38332562)
15. Matuk R., Crawford J., Abreu M. T., Targan S. R., Vasiliauskas E. A., Papadakis K. A., The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease Inflammatory Bowel Diseases 2004 10 4 352 356 (Pubitemid 39029177)
16. Feagins L. A., Cryer B. L., Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Digestive Diseases and Sciences 2010 55 2 226 232
17. Rubin D. T., LoSavio A., Yadron N., Huo D., Hanauer S. B., Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis Clinical Gastroenterology and Hepatology 2006 4 11 1346 1350 (Pubitemid 44716744)
18. Velayos F. S., Terdiman J. P., Walsh J. M., Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies American Journal of Gastroenterology 2005 100 6 1345 1353 (Pubitemid 40904360)
19. Bernstein C. N., Nugent Z., Blanchard J. F., 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study American Journal of Gastroenterology 2011 106 4 731 736
20. Lyakhovich A., Gasche C., Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine Alimentary Pharmacology and Therapeutics 2010 31 2 202 209
21. Reinacher-Schick A., Seidensticker F., Petrasch S., Reiser M., Philippou S., Theegarten D., Freitag G., Schmiegel W., Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel Endoscopy 2000 32 3 245 254 (Pubitemid 30103489)
22. Bus P. J., Nagtegaal I. D., Verspaget H. W., Lamers C. B. H. W., Geldof H., van Krieken J. H. J. M., Griffioen G., Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Alimentary Pharmacology and Therapeutics 1999 13 11 1397 1402 (Pubitemid 29516250)
23. Ikeda I., Tomimoto A., Wada K., Fujisawa T., Fujita K., Yonemitsu K., Nozaki Y., Endo H., Takahashi H., Yoneda M., Inamori M., Kubota K., Saito S., Nagashima Y., Nakagama H., Nakajima A., 5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model Clinical Cancer Research 2007 13 21 6527 6531 (Pubitemid 350075044)
24. Clapper M. L., Gary M. A., Coudry R. A., Litwin S., Chang W. C. L., Devarajan K., Lubet R. A., Cooper H. S., 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis Inflammatory Bowel Diseases 2008 14 10 1341 1347
25. Reinacher-Schick A., Schoeneck A., Graeven U., Schwarte-Waldhoff I., Schmiegel W., Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells Carcinogenesis 2003 24 3 443 451 (Pubitemid 36432639)
26. Stolfi C., Fina D., Caruso R., Caprioli F., Sarra M., Fantini M. C., Rizzo A., Pallone F., Monteleone G., Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid Biochemical Pharmacology 2008 75 3 668 676
27. Stolfi C., Fina D., Caruso R., Caprioli F., Fantini M. C., Rizzo A., Sarra M., Pallone F., Monteleone G., Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase Carcinogenesis 2008 29 6 1258 1266 (Pubitemid 351958707)
28. Shapiro G. I., Cyclin-dependent kinase pathways as targets for cancer treatment Journal of Clinical Oncology 2006 24 11 1770 1783 (Pubitemid 46628473)
29. Luciani M. G., Campregher C., Fortune J. M., Kunkel T. A., Gasche C., 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint Gastroenterology 2007 132 1 221 235 (Pubitemid 46108738)
30. Koelink P. J., Mieremet-Ooms M. A. C., Corver W. E., Wolanin K., Hommes D. W., Lamers C. B. H. W., Verspaget H. W., 5-Aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes Inflammatory Bowel Diseases 2010 16 3 379 389
31. Baan B., Dihal A. A., Hoff E., 5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut. In press
32. Lengauer C., Kinzler K. W., Vogelstein B., Genetic instabilities in human cancers Nature 1998 396 6712 643 649 (Pubitemid 29003936)
33. Ionov Y., Peinado M. A., Malkhosyan S., Shibata D., Perucho M., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis Nature 1993 363 6429 558 561 (Pubitemid 23186645)
34. Gasche C., Goel A., Natarajan L., Boland C. R., Mesalazine improves replication fidelity in cultured colorectal cells Cancer Research 2005 65 10 3993 3997 (Pubitemid 40775634)
35. Campregher C., Honeder C., Chung H., Carethers J. M., Gasche C., Mesalazine reduces mutations in transforming growth factor receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats Clinical Cancer Research 2010 16 6 1950 1956
36. Kastan M. B., Bartek J., Cell-cycle checkpoints and cancer Nature 2004 432 7015 316 323 (Pubitemid 39551659)
37. Bienz M., Clevers H., Linking colorectal cancer to Wnt signaling Cell 2000 103 2 311 320
38. Bos C. L., Diks S. H., Hardwick J. C., Walburg K. V., Peppelenbosch M. P., Richel D. J., Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/ -catenin pathway activity Carcinogenesis 2006 27 12 2371 2382 (Pubitemid 44884094)
39. Ratcliffe M. J., Itoh K., Sokol S. Y., A positive role for the PP2A catalytic subunit in Wnt signal transduction Journal of Biological Chemistry 2000 275 46 35680 35683
40. Jorissen R. N., Walker F., Pouliot N., Garrett T. P. J., Ward C. W., Burgess A. W., Epidermal growth factor receptor: mechanisms of activation and signalling Experimental Cell Research 2003 284 1 31 53 (Pubitemid 36331965)
41. Svrcek M., Cosnes J., Tiret E., Bennis M., Parc Y., Fléjou J. F., Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer Virchows Archiv 2007 450 2 243 244 (Pubitemid 46295226)
42. Spano J. P., Lagorce C., Atlan D., Milano G., Domont J., Benamouzig R., Attar A., Benichou J., Martin A., Morere J. F., Raphael M., Penault-Llorca F., Breau J. L., Fagard R., Khayat D., Wind P., Impact of EGFR expression on colorectal cancer patient prognosis and survival Annals of Oncology 2005 16 1 102 108 (Pubitemid 40124486)
43. Monteleone G., Franchi L., Fina D., Caruso R., Vavassori P., Monteleone I., Calabrese E., Naccari G. C., Bellinvia S., Testi R., Pallone F., Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells Cell Death and Differentiation 2006 13 2 202 211 (Pubitemid 43102204)
44. Matthiessen M. W., Pedersen G., Albrektsen T., Adamsen S., Fleckner J., Brynskov J., Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas Scandinavian Journal of Gastroenterology 2005 40 2 198 205 (Pubitemid 40189001)
45. Tanaka T., Kohno H., Yoshitani S. I., Takashima S., Okumura A., Murakami A., Hosokawa M., Ligands for peroxisome proliferator-activated receptors and inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Research 2001 61 6 2424 2428 (Pubitemid 32685818)
46. Osawa E., Nakajima A., Wada K., Ishimine S., Fujisawa N., Kawamori T., Matsuhashi N., Kadowaki T., Ochiai M., Sekihara H., Nakagama H., Peroxisome proliferator-activated receptor ligands suppress colon carcinogenesis induced by azoxymethane in mice Gastroenterology 2003 124 2 361 367 (Pubitemid 36169253)
47. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G. C., Chavatte P., Farce A., Bulois P., Cortot A., Colombel J. F., Desreumaux P., Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor- Journal of Experimental Medicine 2005 201 8 1205 1215 (Pubitemid 40629065)
48. Desreumaux P., Ghosh S., Review article: mode of action and delivery of 5-aminosalicylic acidnew evidence Alimentary Pharmacology and Therapeutics 2006 24 1 2 9 (Pubitemid 44267773)
49. Schwab M., Reynders V., Loitsch S., Shastri Y. M., Steinhilber D., Schrder O., Stein J., PPAR is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells Carcinogenesis 2008 29 7 1407 1414
50. Stolfi C., Sarra M., Caruso R., Fantini M. C., Fina D., Pellegrini R., Palmieri G., Macdonald T. T., Pallone F., Monteleone G., Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine Gastroenterology 2010 138 1 221 230
51. Stolfi C., Caruso R., Franz E., Rizzo A., Rotondi A., Monteleone I., Fantini M. C., Pallone F., Monteleone G., 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine, sensitizes colon cancer cells to trail-induced apoptosis by regulating death receptor 5 and survivin expression Molecular Cancer Therapeutics 2011 10 10 1969 1981
52. Almasan A., Ashkenazi A., Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine and Growth Factor Reviews 2003 14 3-4 337 348 (Pubitemid 36693152)
53. Lu M., Strohecker A., Chen F., Kwan T., Bosman J., Jordan V. C., Cryns V. L., Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels Clinical Cancer Research 2008 14 10 3168 3176
54. Honeder C., Campregher C., Zens B., Scharl T., Gasche C., Improvement of replication fidelity by certain mesalazine derivatives International Journal of Oncology 2012 40 5 1331 1338